REVIVA PHARMACEUTICALS HOLDINGS, INC. 8-K

What Happened

• Reviva Pharmaceuticals Holdings, Inc. (RVPH) announced in an 8-K that Nasdaq’s Hearings Panel determined to delist the company’s common stock for failing to meet Nasdaq Listing Rule 5550(a)(2) (the $1.00 minimum bid-price requirement). The company received the delisting notice on May 12, 2026 after the maximum discretionary compliance period expired on May 11, 2026.
• Trading of RVPH will be suspended on The Nasdaq Capital Market at the open on May 14, 2026. Beginning May 14, 2026, Reviva’s common stock will be quoted on the OTCQB Venture Market under the symbol “RVPH.” The 8-K also supplements the company’s Risk Factors in its Form 10-K (filed March 30, 2026).

Key Details

• Nasdaq delisting determined by Nasdaq Listing Rule 5550(a)(2) — minimum $1.00 bid-price requirement.
• Company received the Panel’s delisting letter on May 12, 2026; last discretionary compliance date was May 11, 2026.
• Trading suspended on Nasdaq as of market open May 14, 2026; quotation on the OTCQB begins May 14, 2026 under symbol RVPH.
• 8-K updates risk-factor disclosure describing impacts such as reduced liquidity, potential “penny stock” classification, harder access to equity financing, possible loss of analyst coverage, and additional delisting risk on the OTCQB.

Why It Matters

• For investors, the move from Nasdaq to the OTCQB generally means lower liquidity and potentially wider bid-ask spreads, which can make it harder to buy or sell shares and may depress market value.
• The company explicitly warns the delisting could hinder its ability to raise equity capital, provide employee equity incentives, and retain analyst coverage. These are material considerations for current and prospective shareholders evaluating marketability and long-term financing prospects.
• The 8-K includes standard forward-looking cautionary language; shareholders should review the updated Risk Factors in the company’s filings for more detail.